As shown in Fig. 2, overweight/obesity was independently associated with a poor response to neoadjuvant targeted therapy despite the patient’s age, tumor size, nodal status, hormone receptor status, Ki67 expression, or neoadjuvant targeted therapy. This evidence concerns the gene NR4A1 and obesity due to melanocortin 4 receptor deficiency.